Physician profile
Roger E Teller
NPI 1992747372
$1,229.55
in general payments reported to CMS, 2019-2025
14 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.91 · 2021: $22.73 · 2022: $290 · 2023: $576 · 2024: $60.43 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771 · Travel and Lodging: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.74 |
| Travel and Lodging | $121.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $434.27 | 2022-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Smith+Nephew, INC. | $188.10 | 2022-2024 | Collagenase Santyl, Regranex, Pico 7 |
| Organogenesis INC. | $168.53 | 2021-2023 | Puraply |
| Stryker Corporation | $157.09 | 2025 | Limflow System |
| Next Science LLC | $55.65 | 2023 | Blastx, Xperience, Surgx |
| Polymedics Innovations INC. | $43.53 | 2023 | |
| Tactile Systems Technology INC | $41.33 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Integra Lifesciences Corporation | $32.81 | 2025 | Tcc-Ez |
| Misonix INC | $23.91 | 2020 | |
| Abbvie INC. | $21.68 | 2023 | Dalvance |
| Reprise Biomedical, INC. | $17.98 | 2025 | Miro3d |
| Aroa Biosurgery Incorporated | $17.28 | 2022 | |
| Mimedx Group, INC. | $14.68 | 2024 | |
| Paratek Pharmaceuticals, INC. | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Teller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.